Serotonin receptor ligands: Treatments of acute migraine and cluster headache

Handbook of Experimental Pharmacology

Volumn 177, Issue , 2007, Pages 129-143

  Goadsby, P J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cluster headache; Migraine; Trigeminovascular; Triptans

Indexed keywords

LIGAND; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TRYPTAMINE DERIVATIVE;

ACUTE DISEASE; ANIMAL; CENTRAL NERVOUS SYSTEM; CLUSTER HEADACHE; DRUG EFFECT; HUMAN; MIGRAINE; PERIPHERAL NERVOUS SYSTEM; REVIEW;

ACUTE DISEASE; ANIMALS; CENTRAL NERVOUS SYSTEM; CLUSTER HEADACHE; HUMANS; LIGANDS; MIGRAINE DISORDERS; PERIPHERAL NERVOUS SYSTEM; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 34249279608     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-33823-9_5     Document Type: Article

References (126)

1. Adham N, Kao HT, Schechter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA (1993) Cloning of another human serotonin receptor (5- HT1F) : a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 90:408-412
2. Afridi S, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RSJ, Goadsby PJ (2005) A positron emission tomographic study in spontaneous migraine. Arch Neurol 62: 1270-1275
3. Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ (2001) Brainstem activation specific to migraine headache. Lancet 357:1016-1017
4. Bartsch T, Goadsby PJ (2002) Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 125:1496-1509
5. BartschT, Goadsby PJ (2003) Increased responses in trigeminocervicalnociceptive neurones to cervical input after stimulation of the dura mater. Brain 126:1801-1813
6. Bartsch T, Knight YE, Goadsby PJ (2004) Activation of 5-HT1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann Neurol 56:371-381
7. Benedetti F, Arduino C, Amanzio M (1999) Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci 19:3639-3648
8. Bolay H, Reuter U, Dunn AK, Huang Z, Boas D.A., Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in amigrainemodel.NatMed 8:136-142
9. Bouchelet I, Cohen Z, Case B, Hamel E (1996) Differential expression of sumatriptansensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 50:219-223
10. Branchek T, Archa JE (1997) Recent advances in migraine therapy. In: Robertson DW (ed) Central nervous system disease. Academic Press, San Diego, pp 1-10
11. Burstein R, Yamamura H, Malick A, Strassman AM (1998) Chemical stimulation of the intracranialdura induces enhancedresponses to facial stimulationin brain stemtrigeminal neurons. J Neurophysiol 79:964-982
12. Burstein R, Cutrer MF, Yarnitsky D (2000a) The development of cutaneous allodynia during a migraine attack. Brain 123:1703-1709
13. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000b) An association between migraine and cutaneous allodynia. Ann Neurol 47:614-624
14. Castro ME, Pascual J, Romon T, del Arco C, del Olmo E, Pazos A (1997) Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 36:535-542
15. Classey JD, Bartsch T, Goadsby PJ (2002) Immunohistochemical examination of 5HT1B, 5HT1D and 5HT1F receptor expression in rat trigeminal ganglion (TRG) and dorsal root ganglia (DRG) neurons. Cephalalgia 22:595-596
16. Cohen AS, Matharu MS, Kalisch R, Friston K, Goadsby PJ (2004) Functional MRI in SUNCT shows differential hypothalamic activation with increasing pain. Cephalalgia 24: 1098-1099
17. Cohen ML, Schenck K (1999) 5-Hydroxytryptamine (1F) receptors do not participate in vasoconstriction: lackof vasoconstrictiontoLY344864, a selective serotonin (1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 290:935-939
18. Connor HE, Bertin L, Gillies S, Beattie DT, Ward P, The GR205171 Clinical Study Group (1998) Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia 18:392
19. Cumberbatch MJ, Hill RG, Hargreaves RJ (1997) Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 328:37-40
20. CumberbatchMJ, Hill RG, Hargreaves RJ (1998) Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 18:659-664
21. Cutrer FM, Limmroth V, Waeber C, Yu X, Moskowitz MA (1997) New targets for antimigraine drug development. In: Goadsby PJ, Silberstein SD (eds) Headache. Butterworth- Heinemann, Philadelphia, pp 59-72
22. Data J, Britch K, Westergaard N, Weihnuller F, Harris S, Swarz H, Silberstein S, Goldstein J, Ryan R, Saper J, Londborg P, Winner P, Klapper J (1998) A double-blind study of ganaxolone in the acute treatment of migraine headaches with or without an aura in premenopausal females. Headache 38:380
23. De Vries P, Villalon CM, Saxena PR (1999) Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 375: 61-74
24. Diener HC, The RPR100893 Study Group (2003) RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23:183-185
25. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC (1991) Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 44:97-112
26. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA (1992) Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 48:187-203
27. Dodick D, Lipton RB, Martin V, Papademetriou V, RosamondW, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J (2004) Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 44: 414-425
28. Doenicke A, Siegel E, Hadoke M, Perrin VL (1987) Initial clinical study of AH25086B (5- HT1-like agonist) in the acute treatment of migraine. Cephalalgia 7:437-438
29. Doenicke A, Brand J, Perrin VL (1988) Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1:1309-1311
30. Durham PL, Russo AF (1999) Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci 19:3423-3429
31. Durham PL, Sharma RV, Russo AF (1997) Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J Neurosci 17:9545-9553
32. Earl NL, McDonald SA, Lowy MT, 4991W93 Investigator Group (1999) Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine. Cephalalgia 19:357
33. Ebersberger A, Schaible HG, Averbeck B, Richter F (2001) Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol 49:7-13
34. Edvinsson L (1999) Experimental headache models in animals and man. Martin Dunitz, London
35. Feindel W, Penfield W, McNaughton F. 1960. The tentorial nerves and localization of intracranial pain in man. Neurology. 10: 555-563
36. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: ameta-analysis of 53 trials. Lancet 358:1668-1675
37. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633-658
38. Fleishaker JC, Pearson LK, Knuth DW, GomezMancilla B, Francom SF, McIntoshMJ, Freestone S, Azie NE (1999) Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F. Int J Clin Pharmacol Ther 37:487-492
39. Fugelli A, Moret C, Fillion G (1997) Autoradiographic localization of 5-HT1E and 5-HT1F binding sites in rat brain: effect of serotonergic lesioning. J Recept Signal Transduct Res 17:631-645
40. Goadsby PJ (2000) The pharmacology of headache. Prog Neurobiol 62:509-525
41. Goadsby PJ (2001) Migraine, aura and cortical spreading depression:why are we still talking about it? Ann Neurol 49:4-6
42. Goadsby PJ, Classey JD (2003) Evidence for5-HT1B, 5-HT1Dand5-HT1Freceptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122:491-498
43. Goadsby PJ, Hoskin KL (1996) Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT) 1B/D receptor agonist zolmitriptan (311C90) : are brain stem sites a therapeutic target in migraine? Pain 67:355-359
44. Goadsby PJ, Hoskin KL (1997) The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 190:367-375
45. Goadsby PJ, Hoskin KL (1999) Differential effects of low dose CP122, 288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain 82:15-22
46. Goadsby PJ, Kaube H (2000) Animal models of headache. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The headaches. Lippincott Williams and Wilkins, Philadelphia, pp 195-202
47. Goadsby PJ, Knight YE (1997) Inhibition of trigeminal neurons after intravenous administration of naratriptan through an action at the serotonin (5HT1B/1D) receptors. Br J Pharmacol 122:918-922
48. Goadsby PJ, Zagami AS (1991) Stimulation of the superior sagittal sinus increasesmetabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 114:1001-1011
49. Goadsby PJ, HoskinKL, KnightYE (1997) Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. Pain 73:23-28
50. Goadsby PJ, Akerman S, Storer RJ (2001) Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex. Ann Neurol 50:804-807
51. Goadsby PJ, LiptonRB, FerrariMD (2002) Migraine-current understanding and treatment. N Engl J Med 346:257-270
52. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acutemigraine: a crossover study. Cephalalgia 17:785-790
53. Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001) Selective serotonin 1F [5-HT (1F) ] receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358:1230-1234
54. Gomez-Mancilla B, Cutler NR, Leibowitz MT, Spierings ELH, Klapper JA, Diamond S, Goldstein J, Smith T, Couch JR, Fleishaker J, Azie N, Blunt DE (2001) Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acutemigraine. Cephalalgia 21:727-732
55. Harrison SD, Balawi SA, Feinmann C, Harris M (1997) Atypical facial pain: a double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan. Eur Neuropsychopharmacol 7:83-88
56. Hoskin KL, Kaube H, Goadsby PJ (1996) Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiology study. Brain 119:249-256
57. Hoskin KL, Zagami A, Goadsby PJ (1999) Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 194:579-588
58. Hoskin KL, Bulmer DCE, Lasalandra M, Jonkman A, Goadsby PJ (2001) Fos expression in themidbrain periaqueductal grey after trigeminovascular stimulation. J Anat 197:29-35
59. Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET (1990) Serotonin and migraine. Ann NY Acad Sci 600:587-598
60. Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ (1997) Possible mechanism of c-fos expression in trigeminal nucleus caudalis following spreading depression. Pain 72: 407-415
61. Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ (1998) Comment on Ingvardsen et al., Pain 72 (1997) 407-415-reply to Moskowitz et al. Pain 76:266-267
62. Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME, Adham N, Zgombick JM, Cohen ML, Branchek TA, Phebus LA (1997) 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. NeuroReport 8:2237-2240
63. Johnston BM, Saxena PR (1978) The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 63: 541-549
64. Kaube H, Hoskin KL, Goadsby PJ (1992) Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia 12:133-136
65. Kaube H, Hoskin KL, Goadsby PJ (1993a) Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 109:788-792
66. Kaube H, Hoskin KL, Goadsby PJ (1993b) Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33:541-550
67. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ (1993c) Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. Brain Res 629:95-102
68. Kimball RW, Friedman AP, Vallejo E (1960) Effect of serotonin in migraine patients. Neurology 10:107-111
69. Knight YE, Goadsby PJ (2001) The periaqueductal graymattermodulates trigeminovascular input: a role in migraine? Neuroscience 106:793-800
70. Knight YE, Bartsch T, Kaube H, Goadsby PJ (2002) P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 22:1-6
71. Knight YE, Bartsch T, Goadsby PJ (2003) Trigeminal antinociception induced by bicuculline in the periaqueductal grey (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. Neurosci Lett 336:113-116
72. LambertGA, LowyAJ, BoersP, Angus-LeppanH, ZagamiA (1992) Thespinal cordprocessing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. Brain Res 597:321-330
73. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS (2002) Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res 953:181-188
74. Lance JW, Fine RD, Curran D.A.(1963) An evaluation of methysergide in the prevention of migraine and other vascular headache. Med J Aust 1:814-818
75. Lance JW, Anthony M, Hinterberger H (1967) The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 7:93-102
76. Levy D, Jakubowski M, Burstein R (2004) Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 101:4274-4279
77. Lipton RB, StewartWF, CadyR, Hall C, OQuinn S, Kuhn T, GuttermanD (2000) Sumatriptan for the range of headaches inmigraine sufferers: results of the SpectrumStudy.Headache 40:783-791
78. Maneesi S, Akerman S, LasalandraMP, Classey JD, Goadsby PJ (2004) Electron microscopic demonstration of pre- and postsynaptic 5-HT1D and 5-HT1F receptorimmunoreactivity (IR) in the rat trigeminocervical complex (TCC) new therapeutic possibilities for the triptans. Cephalalgia 24:148
79. Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129-4136
80. Markowitz S, Saito K, MoskowitzMA (1988) Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8:83-91
81. Matharu MS, Goadsby PJ (2004) Cluster headache: a review with a focus on emerging therapies. Expert Rev Neurother 4:895-907
82. May A, Gijsman HJ, Wallnoefer A, Jones R, Diener HC, Ferrari MD (1996) Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67:375-378
83. May A, Bahra A, Buchel C, Frackowiak RSJ, Goadsby PJ (1998a) Hypothalamic activation in cluster headache attacks. Lancet 352:275-278
84. May A, Shepheard S, Wessing A, Hargreaves RJ, Goadsby PJ, Diener HC (1998b) Retinal plasma extravasation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. Brain 121:1231-1237
85. May A, Bahra A, Buchel C, Turner R, Goadsby PJ (1999) Functional MRI in spontaneous attacks of SUNCT: short-lasting neuralgiformheadache with conjunctival injection and tearing. Ann Neurol 46:791-793
86. McCall RB, Huff R, Chio CL, TenBrink R, Bergh CL, Ennis MD, Ghazal NB, Hoffman RL, Meisheri K, HigdonNR, HallE (2002) Preclinical studies characterizing theanti-migraine and cardiovascular effects of the selective 5-HT 1D receptor agonist PNU-142633.Cephalalgia 22:799-806
87. McNaughton FL (1966) The innervation of the intracranial blood vessels and the dural sinuses. In: Cobb S, Frantz AM, Penfield W, Riley HA (eds) The circulation of the brain and spinal cord. Hafner Publishing, New York, pp 178-200
88. Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, Waeber C (1999) Both 5-HT1B and 5-HT1F receptorsmodulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 369:271-277
89. Morgan JI, Curran T (1991) Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14:421-451
90. Moskowitz MA (1990) Basic mechanisms in vascular headache. Neurol Clin 8:801-815
91. MoskowitzMA, Cutrer FM (1993) Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 44:145-154
92. Moskowitz MA, Nozaki K, Kraig RP (1993) Neocortical spreading depression provokes the expression of C-fos protein-like immunoreactivity within the trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167-1177
93. Norman B, Panebianco D, Block GA (1998) A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758, 298 (a prodrug of the NK1 receptor antagonist L-754, 030) in the acute treatment of migraine. Cephalalgia 18:407
94. Nozaki K, Boccalini P, Moskowitz MA (1992) Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience 49:669-680
95. Pascual J, Arco Cd, Romon T, Olmo Cd, Pazos A (1996) [3H] Sumatriptan binding sites in human brain: regional-dependent labelling of 5HT1D and 5HT1F receptors. Eur J Pharmacol 295:271-274
96. PenfieldW (1932a) Intracerebral vascular nerves. AMA Arch Neurol Psychiatry 27:30-44
97. Penfield W (1932b) Operative treatment of migraine and observations on the mechanism of vascular pain. Trans Am Acad Ophthalmol Otolaryngol III:1-16
98. Penfield W (1934) A contribution to the mechanism of intracranial pain. Proc Assoc Res Nerv Mental Dis 15:399-415
99. PenfieldW, McNaughton FL (1940) Dural headache and the innervation of the dura mater. AMA Arch Neurol Psychiatry 44:43-75
100. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DLG, Calligaro DO, Kiefer AD, Branchek TA, Flaugh ME (1997) Characterization of LY334370 as a pharmacological tool to study 5HT1F receptors-binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61: 2117-2126
101. Potrebic S, Ahan AH, Skinner K, Fields HL, Basbaum AI (2003) Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 23:10988-10997
102. Pozo-Rosich P, OshinskyM (2005) Effect of dihydroergotamine (DHE) on central sensitisation of neurons in the trigeminal nucleus caudalis. Neurology 64:A151
103. Pregenzer JF, Alberts GL, Block JH, Slightom JL, Im WB (1997) Characterisation of ligand binding properties of the 5-HT1D receptors cloned fromchimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors. Neurosci Lett 235:117-120
104. Pregenzer JF, Alberts GL, Im WB, Slightom JL, Ennis MD, Hoffman RL, Ghazal NB, Ten- Brink RE (1999) Differential pharmacology between the guinea-pig and the gorilla 5- HT1D receptor as probed with isochromans (5-HT1D-selective ligands) . Br J Pharmacol 127:468-472
105. Raskin NH, Hosobuchi Y, Lamb S (1987) Headache may arise from perturbation of brain. Headache 27:416-420
106. Ray BS, Wolff HG (1940) Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 41:813-856
107. Razzaque Z, Heald MA, Pickard JD, Maskell L, Beer MS, Hill RG, Longmore J (1999) Vasoconstriction in human isolatedmiddlemeningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol 47:75-82
108. Roon K, Diener HC, Ellis P, Hettiarachchi J, Poole P, Christiansen I, Ferrari MD, Olesen J (1997) CP-122, 288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia 17:245
109. Saxena PR, Cairo-Rawlins WI (1979) Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat. Eur J Pharmacol 58:305-312
110. Saxena PR, De BoerMO (1991) Pharmacology of antimigraine drugs. J Neurol 238:S28-S35
111. Selby G, Lance JW (1960) Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 23:23-32
112. Shields KG, Goadsby PJ (2004) Naratriptanmodulates trigeminovascular nociceptive transmission in the ventroposteromedial (VPM) thalamic nucleus of the rat. Cephalalgia 24:1098
113. Shields KG, Goadsby PJ (2005) Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 128:86-97
114. Shields KG, Kaube H, Goadsby PJ (2003) GABA receptors modulate trigeminovascular nociceptive transmission in the ventroposteromedial (VPM) thalamic nucleus of the rat. Cephalalgia 23:728
115. Steuer H, Jaworski A, Stoll D, Schlosshauer B (2004) In vitromodel of the outer blood-retina barrier. Brain Res Brain Res Protoc 13:26-36
116. Storer RJ, Goadsby PJ (1997) Microiontophoretic application of serotonin (5HT) 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 120:2171-2177
117. Strassman AM, Raymond SA, Burstein R (1996) Sensitization ofmeningeal sensory neurons and the origin of headaches. Nature 384:560-563
118. Veloso F, Kumar K, Toth C (1998) Headache secondary to deep brain implantation.Headache 38:507-515
119. Waeber C, MoskowitzMA (1995) [3H]Sumatriptan labels both 5-HT1D and 5HT1F receptor bindings sites in the guinea pig brain: an autoradiographic study.Naunyn Schmiedebergs Arch Pharmacol 352:263-275
120. Waeber C, Cutrer FM, Yu XJ, MoskowitzMA (1997) The selective 5HT1D receptor agonist U- 109291 blocks dural plasma extravasation and c-fos expression in the trigeminal nucleus caudalis. Cephalalgia 17:401
121. Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL (1998) Human 5-HT1F receptor-stimulated [S-35]GTP gamma S binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol 352:117-124
122. Weiller C, May A, Limmroth V, JuptnerM, Kaube H, Schayck RV, Coenen HH, Diener HC (1995) Brain stemactivation in spontaneous humanmigraine attacks.NatMed 1:658-660
123. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 17:525-531
124. Wolff HG (1948) Headache and other head pain. Oxford University Press, New York
125. Zagami AS, Goadsby PJ. 1991. Stimulation of the superior sagittal sinus increasesmetabolic activity in cat thalamus, Rose FC (ed), New advances in headache research: 2. Smith- Gordon, London. 169-171
126. ZagamiAS, LambertGA (1991) Craniovascular applicationof capsaicin activatesnociceptive thalamic neurons in the cat. Neurosci Lett 121:187-190